Avtor/Urednik		Levičar, Nataša
Naslov		Vrednotenje proteoliznih encimov in njihovih inhibitorjev kot prognostičnih pokazateljev karcinoma dojke
Tip		monografija
Kraj izdaje		Ljubljana
Založnik		Medicinska fakulteta
Leto izdaje		1999
Obseg		str. 54
Jezik		slo
Abstrakt		Proteolytic enzymes have been proposed as the new potentail biological prognostic factors for breast cancer patients. Determination of their concentrations in primary tumours may facilitate decision about treatment of breast cancer patients, following the removal of the tumor. Previous investigations have shown, that increased expression of cysteine proteinases cathepsins B and L (CatB and CatL) and urokinase-type plasminogen activator (uPA) in tumor, compared to normal breast tissue, were associated with breast tumour progression. Similarly, altered levels of their endogenous inhibitors stefins A and B (StA and StB) and plasminogen activator inhibitor-1 (PAI-1) were found in malignant tumours. We determined the levels of CatB, CatL, StA, StB, uPA and PAI-1 in 150 primary invasive ductal carcinoma and 83 matched control breast tissues by measuring activity and by ELISA. Proteinases and their inhibitors were found 2-12 fold increased in tumour tissue compared with the controls. Good correlation was found between tumour levels of CatB and CatL (r=0.65). Weak correlation was found between uPA and PAI-1 (r=0.41) and very low correlation between CatB and uPA (r=0.32). Cathepsins and stefins were not related with standard clinical and histopathological factors indicating tumour progression. In contrast, elevated levels of uPA correlated well with the histological grade (p<0.00) and with positive ER (p<0.01), while PAI-1 correlated with all histopahological factors, except tumour size. We evaluated and compared the prognostic impact of all these biological factors. Increased levels of uPA and PAI-1 had the most significant impact on shorter disease-free survival (DFS) (p<0.00, p<0.02, respectively) and overall survival (OS) (p,0.00, p,0.05, respevtively). (Abstract truncated at 2000 characters.)
Deskriptorji		BREAST NEOPLASMS CATHEPSIN B CYSTEINE PROTEINASE INHIBITORS UROKINASE PLASMINOGEN ACTIVATOR INHIBITOR 1 CATHEPSINS RECEPTORS, ESTROGEN RECEPTORS, PROGESTERONE ENZYME-LINKED IMMUNOSORBENT ASSAY SURVIVAL ANALYSIS PROGNOSIS NEOPLASM STAGING